Tourmaline Bio: Looking To Go Beyond FcRn Inhibition With IL-6 Targeting

Core Insights - Tourmaline Bio (NASDAQ: TRML) is expected to have several catalysts in 2025 that could significantly enhance shareholder value [2]. Company Overview - Tourmaline Bio is involved in various programs aimed at generating substantial shareholder value [2]. Investment Analysis - The Biotech Analysis Central service provides in-depth analysis of pharmaceutical companies, including a library of over 600 articles and a model portfolio of small and mid-cap stocks [2].